STOCK TITAN

Livanova Plc - LIVN STOCK NEWS

Welcome to our dedicated page for Livanova Plc news (Ticker: LIVN), a resource for investors and traders seeking the latest updates and insights on Livanova Plc stock.

LivaNova PLC (LIVN) is a global leader in medical technology innovation, specializing in life-supporting cardiopulmonary solutions and neuromodulation therapies. This dedicated news hub provides investors and healthcare professionals with essential updates on the company’s clinical advancements, regulatory milestones, and strategic initiatives.

Track all official LivaNova press releases, earnings reports, and product development announcements in one centralized resource. Our curated news feed covers critical developments including FDA clearances, international expansion efforts, and partnerships shaping the future of cardiac surgery and neurological treatment technologies.

Key updates feature progress in extracorporeal circulation systems, enhancements to vagus nerve stimulation therapies, and sustainability initiatives across global manufacturing operations. The platform serves as a vital tool for monitoring how LivaNova’s innovations in heart-lung machines and depression treatment devices impact both patient outcomes and shareholder value.

Bookmark this page for immediate access to verified information about LIVN’s market position, intellectual property developments, and leadership changes. Stay informed about the medical technology pioneer driving advancements in critical care through its merged heritage of European and American engineering excellence.

Rhea-AI Summary
LivaNova PLC's Interim CEO and Board Chair, Bill Kozy, will present a general business update at two healthcare conferences in New York in November.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.57%
Tags
conferences
-
Rhea-AI Summary
LivaNova appoints J. Christopher Barry to its Board of Directors and announces the retirement of Andrea Saia
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.75%
Tags
management
-
Rhea-AI Summary
LivaNova announces retirement of President of Cardiopulmonary Business Unit, Marco Dolci, by December 31, 2023. Franco Poletti appointed as Interim General Manager. A search for a permanent successor will be conducted. Dolci's leadership during the pandemic and launch of Essenz Perfusion System acknowledged. Smooth transition expected.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.29%
Tags
none
Rhea-AI Summary
LivaNova to discuss Q3 2023 results in conference call on November 1, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.35%
Tags
-
Rhea-AI Summary
LivaNova receives FDA clearance for Essenz In-Line Blood Monitor, enhancing patient care during cardiopulmonary bypass procedures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.02%
Tags
-
Rhea-AI Summary
LivaNova CEO to present at Baird Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
conferences
Rhea-AI Summary
LivaNova PLC (Nasdaq: LIVN) reported Q2 2023 results with a 15.6% increase in revenue to $293.9 million and raised full-year 2023 guidance. Cardiopulmonary revenue increased by 20.9% and Neuromodulation revenue increased by 13.5% compared to the prior year. Adjusted diluted earnings per share for 2023 are expected to be in the range of $2.55 to $2.75.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.87%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.81%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.19%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
none
Livanova Plc

Nasdaq:LIVN

LIVN Rankings

LIVN Stock Data

1.85B
54.14M
0.33%
104.41%
2.91%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United Kingdom
LONDON